SMARCA4 and cancer: The 5th edition of the WHO classification of thoracic tumors recognized SMARCA4-deficient undifferentiated tumors as a distinct entity, characterizing them as malignant neoplasms with an undifferentiated or rhabdoid phenotype resulting from SMARCA4 (BRG1) deficiency (10).